Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alnylam; Quark; Alcon; and More

Premium

Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Solid Cancers

Patent Number: 8,148,069

Filed: Jan. 3, 2007

Lead Inventor: Carlo Croce, Ohio State University

The invention provides “novel methods and compositions for the diagnosis and treatment of solid cancers,” the patent's abstract states. “The invention also provides methods of identifying inhibitors of tumorigenesis.”


Title: pCryptoRNAi

Patent Number: 8,148,144

Filed: March 25, 2009

Lead Inventor: Jon Ander Ochoa de Eribe Casas, Chiba University

The invention, the patent's abstract states, relates to “a vector developed to transform fungi [that] can be used to study the expression of a gene of interest. The vector can provide for the expression of signal proteins in fungi that can be observed and/or monitored. The vector can be used to investigate the effects of RNA interference on a gene of interest in pathogenic fungi.”


Title: Oligoribonucleotides and Methods of Use Thereof for Treatment of Alopecia, Acute Renal Failure, and Other Diseases

Patent Number: 8,148,342

Filed: Jan. 11, 2008

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

“The invention relates to a double-stranded compound, preferably an oligoribonucleotide, [that] down-regulates the expression of a human p53 gene,” the patent's abstract states. “The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The ... invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases [by] administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.”


Title: Compositions and Methods for Mediating RNAi In Vivo

Patent Number: 8,148,344

Filed: March 26, 2009

Lead Inventor: Akin Akinc, Alnylam Pharmaceuticals

“This invention relates to new formulated lipid particles comprising at least one of a single- or double-stranded oligonucleotide, where the oligonucleotide has been conjugated to a lipophile and at least one of an emulsion or liposome to which the conjugated oligonucleotide has been aggregated, admixed, or associated,” the patent's abstract states. “These particles have surprisingly been shown to effectively deliver oligonucleotides to heart, lung, and muscle where they effect gene silencing.”


Title: Composition and Method for In Vivo and In Vitro Attenuation of Gene Expression Using Double-Stranded RNA

Patent Number: 8,148,345

Filed: April 13, 2009

Lead Inventor: Yin-Xong Li, Georgia Health Sciences University Research Institute

“Introduction of double-stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, specifically attenuates gene expression,” the patent's abstract states.


Title: Combination Anti-HIV Vectors, Targeting Vectors, and Methods of Use

Application Number: 20120076763

Filed: April 29, 2010

Lead Inventor: Joseph Anderson, University of California, Davis

The invention, the patent application's abstract states, comprises “recombinant lentiviral vectors containing ... a lentiviral backbone [made of] essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element.

“In an alternative aspect, the vector also contains polynucleotides encoding TRIMS alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides,” it adds. “The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.”


Title: Vector

Application Number: 20120076823

Filed: June 11, 2009

Lead Inventor: Venugopal Nair, Institute for Animal Health

The invention relates to “a herpes virus vector which comprises a modified genomic sequence encoding a microRNA against a target sequence,” the patent application's abstract states. “The herpes virus vector may be used as or in a vaccine to prevent and/or treat a disease.”


Title: Polyion Complex of Double-Stranded Ribonucleic Acid

Application Number: 20120076836

Filed: March 31, 2010

Lead Inventor: Yuichi Hori, University of Tokyo

The invention comprises a “delivery system that is useful in delivering a double-stranded ribonucleic acid that functions in gene silencing in glomeruli, particularly in mesangial cells and the like, to the tissue or cells, and the like,” according to the patent application's abstract.


Title: Methods of Determining Potency of Chemically Synthesized Oligonucleotides

Application Number: 20120077276

Filed: Dec. 5, 2011

Lead Inventor: Walter Lima, Isis Pharmaceuticals

The invention comprises “methods for determining potency of RNAi agents,” the patent's abstract states. “Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.”


Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-103-2

Application Number: 20120077699

Filed: Nov. 15, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention “provides novel methods and compositions for the diagnosis and treatment of colon cancers,” the patent application's abstract states. “In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring [miRNA] levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”


Title: Method of Diagnosing Poor Survival Prognosis Colon Cancer Using miR-29a

Application Number: 20120077700

Filed: Nov. 15, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention “provides novel methods and compositions for the diagnosis and treatment of colon cancers,” the patent application's abstract states. “In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring [miRNA] levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”


Title: RNAi-Mediated Inhibition of Gremlin for Treatment of IOP-Related Conditions

Application Number: 20120077864

Filed: Oct. 26, 2011

Lead Inventor: Jon Chatterton, Alcon

“RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma, such as normal tension glaucoma and open-angle glaucoma,” the patent application's abstract states.


Title: Compositions and Methods for Treating Pancreatic Cancer

Application Number: 20120077867

Filed: June 8, 2010

Inventor: Murray Korc, Dartmouth College

The invention provides “a method of treating pancreatic cancer by inhibiting the activity cyclin D1 activity in tumor cells,” the patent application's abstract states. “The invention is based on the finding that cyclin D1 shRNA molecules are capable of attenuating tumor growth and interfering with tumor angiogenesis.”

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.